FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2540391384> ?p ?o ?g. }

• W2540391384 endingPage "79746" @default.
• W2540391384 startingPage "79736" @default.
• W2540391384 abstract "// Siwei Wang 1, 2, * , Mantang Qiu 1, 2, * , Wenjia Xia 1, 2, * , Youtao Xu 1 , Qixing Mao 1, 2 , Jie Wang 1 , Gaochao Dong 1 , Lin Xu 1 , Xin Yang 3 , Rong Yin 1 1 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Biobank of Clinical Resources, Cancer Institute of Jiangsu Province, Nanjing 210009, China 2 The Fourth Clinical College of Nanjing Medical University, Nanjing, 210000, China 3 Department of Oncology, The Third Hospital of Soochow University, Changzhou, 213003, China * These authors have contributed equally to this work Correspondence to: Xin Yang, email: yangxindoctor@163.com Rong Yin, email: yinhero001@126.com Keywords: Glypican-5 (GPC5), lung adenocarcinoma (LAC), Epithelial-Mesenchymal Transition (EMT), Wnt/β-catenin signaling pathway Received: June 30, 2016     Accepted: October 14, 2016     Published: October 27, 2016 ABSTRACT We previously demonstrated that Glypican-5 (GPC5), one of the members of heparan sulfate proteoglycan, was a novel tumor metastasis suppressor in lung adenocarcinoma (LAC). However, it remains unclear how GPC5 suppresses lung cancer metastasis. Here, we found over-expression GPC5 induced significant Epithelial-Mesenchymal Transition (EMT) process of A549 cells in vitro . Bioinformatic analysis of RNA sequencing data indicated that GPC5 was co-expressed with EMT related markers, E-cadherin and Vimentin. Wnt/β-catenin signaling pathway was also significantly enriched after overexpressing GPC5. Further in vitro experiments demonstrated that overexpressing GPC5 could block the translocation of β-catenin from cytoplasm to nucleus and therefore inactivate the Wnt/β-catenin signaling pathway by competitively binding to Wnt3a. Subsequent rescue experiments demonstrated that GPC5-induced metastatic phenotype and EMT process suppression were significantly reversed when cells cultured in Wnt3a conditioned media. By establishing the metastatic model in severe combined immune deficiency (SCID) mice, we also demonstrated that overexpressing GPC5 suppressed LAC migration and accordingly alerted EMT related markers, which including up-regulated E-cadherin and down-regulated Vimentin in both lung and liver metastasis. Finally, clinical samples of LAC further validated that GPC5 expression was positively correlated with E-cadherin, and negatively correlated with both Twist1 and MMP2. Taken together, these data suggested that GPC5 is able to suppress the LAC metastasis by competitively binding to Wnt3a and inactivating the Wnt/β-catenin signaling pathway. Our findings expanded the role and the molecular mechanism of GPC5 on malignant bionomics of LAC." @default.
• W2540391384 created "2016-11-04" @default.
• W2540391384 creator A5001839093 @default.
• W2540391384 creator A5028336314 @default.
• W2540391384 creator A5029989438 @default.
• W2540391384 creator A5036928244 @default.
• W2540391384 creator A5046849313 @default.
• W2540391384 creator A5048580841 @default.
• W2540391384 creator A5053755264 @default.
• W2540391384 creator A5056384869 @default.
• W2540391384 creator A5069913517 @default.
• W2540391384 creator A5075877965 @default.
• W2540391384 date "2016-10-27" @default.
• W2540391384 modified "2023-09-30" @default.
• W2540391384 title "Glypican-5 suppresses Epithelial-Mesenchymal Transition of the lung adenocarcinoma by competitively binding to Wnt3a" @default.
• W2540391384 cites W1767882197 @default.
• W2540391384 cites W1943317391 @default.
• W2540391384 cites W1964847767 @default.
• W2540391384 cites W1968861372 @default.
• W2540391384 cites W1974643611 @default.
• W2540391384 cites W1987473368 @default.
• W2540391384 cites W1998085730 @default.
• W2540391384 cites W2006555393 @default.
• W2540391384 cites W2009765976 @default.
• W2540391384 cites W2063053901 @default.
• W2540391384 cites W2063699975 @default.
• W2540391384 cites W2071635593 @default.
• W2540391384 cites W2072009837 @default.
• W2540391384 cites W2083056328 @default.
• W2540391384 cites W2088484876 @default.
• W2540391384 cites W2089260591 @default.
• W2540391384 cites W2104837386 @default.
• W2540391384 cites W2112208329 @default.
• W2540391384 cites W2118910780 @default.
• W2540391384 cites W2139658078 @default.
• W2540391384 cites W2142626851 @default.
• W2540391384 cites W2148294117 @default.
• W2540391384 cites W2166351918 @default.
• W2540391384 cites W2169379435 @default.
• W2540391384 cites W2170552969 @default.
• W2540391384 cites W2272984102 @default.
• W2540391384 cites W2346220003 @default.
• W2540391384 doi "https://doi.org/10.18632/oncotarget.12945" @default.
• W2540391384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5346747" @default.
• W2540391384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27806326" @default.
• W2540391384 hasPublicationYear "2016" @default.
• W2540391384 type Work @default.
• W2540391384 sameAs 2540391384 @default.
• W2540391384 citedByCount "37" @default.
• W2540391384 countsByYear W25403913842017 @default.
• W2540391384 countsByYear W25403913842018 @default.
• W2540391384 countsByYear W25403913842019 @default.
• W2540391384 countsByYear W25403913842020 @default.
• W2540391384 countsByYear W25403913842021 @default.
• W2540391384 countsByYear W25403913842022 @default.
• W2540391384 countsByYear W25403913842023 @default.
• W2540391384 crossrefType "journal-article" @default.
• W2540391384 hasAuthorship W2540391384A5001839093 @default.
• W2540391384 hasAuthorship W2540391384A5028336314 @default.
• W2540391384 hasAuthorship W2540391384A5029989438 @default.
• W2540391384 hasAuthorship W2540391384A5036928244 @default.
• W2540391384 hasAuthorship W2540391384A5046849313 @default.
• W2540391384 hasAuthorship W2540391384A5048580841 @default.
• W2540391384 hasAuthorship W2540391384A5053755264 @default.
• W2540391384 hasAuthorship W2540391384A5056384869 @default.
• W2540391384 hasAuthorship W2540391384A5069913517 @default.
• W2540391384 hasAuthorship W2540391384A5075877965 @default.
• W2540391384 hasBestOaLocation W25403913841 @default.
• W2540391384 hasConcept C121608353 @default.
• W2540391384 hasConcept C126322002 @default.
• W2540391384 hasConcept C137620995 @default.
• W2540391384 hasConcept C143998085 @default.
• W2540391384 hasConcept C2776256026 @default.
• W2540391384 hasConcept C2778019345 @default.
• W2540391384 hasConcept C2779013556 @default.
• W2540391384 hasConcept C2779742787 @default.
• W2540391384 hasConcept C2781182431 @default.
• W2540391384 hasConcept C502942594 @default.
• W2540391384 hasConcept C54355233 @default.
• W2540391384 hasConcept C62478195 @default.
• W2540391384 hasConcept C71924100 @default.
• W2540391384 hasConcept C76419328 @default.
• W2540391384 hasConcept C86803240 @default.
• W2540391384 hasConceptScore W2540391384C121608353 @default.
• W2540391384 hasConceptScore W2540391384C126322002 @default.
• W2540391384 hasConceptScore W2540391384C137620995 @default.
• W2540391384 hasConceptScore W2540391384C143998085 @default.
• W2540391384 hasConceptScore W2540391384C2776256026 @default.
• W2540391384 hasConceptScore W2540391384C2778019345 @default.
• W2540391384 hasConceptScore W2540391384C2779013556 @default.
• W2540391384 hasConceptScore W2540391384C2779742787 @default.
• W2540391384 hasConceptScore W2540391384C2781182431 @default.
• W2540391384 hasConceptScore W2540391384C502942594 @default.
• W2540391384 hasConceptScore W2540391384C54355233 @default.
• W2540391384 hasConceptScore W2540391384C62478195 @default.
• W2540391384 hasConceptScore W2540391384C71924100 @default.
• W2540391384 hasConceptScore W2540391384C76419328 @default.
• W2540391384 hasConceptScore W2540391384C86803240 @default.

• next